The New England journal of medicineAdultFemaleHumansMaleMiddle Aged
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
Ronald F van Vollenhoven, Li Wang, Joan T Merrill, Yi Liu, Chunde Bao, Fen Li, Jiankang Hu, Chenghui Huang, Jianhong Zhao, Cibo Huang, Hanyou Mo, Wei Wei, Fu'ai Lu, Jingyang Li, Dongbao Zhao
Published: 202510.1056/NEJMoa2414719
Abstract
BACKGROUND: Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) in a phase 2b trial when added to sta…
Preview only. Read the full abstract at the source